Literature DB >> 8021511

Role and effect of TNF-alpha in experimental visceral leishmaniasis.

M C Tumang1, C Keogh, L L Moldawer, D C Helfgott, R Teitelbaum, J Hariprashad, H W Murray.   

Abstract

TNF-alpha has been implicated in cytokine-induced macrophage activation and tissue granuloma formation, two activities linked to control of intracellular visceral infection caused by Leishmania donovani. To determine the role of TNF-alpha in L. donovani-infected BALB/c mice, we measured TNF-alpha levels and treated mice with either anti-TNF-alpha antiserum or TNF-alpha. TNF-alpha activity in infected livers was increased by 2.7-fold 2 wk after challenge and by 5.5-fold at wk 8. In parallel, although control mice acquired resistance by wk 4 and resolved infection by wk 8, liver parasite burdens steadily increased in anti-TNF-alpha-treated animals. Hepatic granuloma formation, however, was not impaired by anti-TNF-alpha. Endogenous TNF-alpha levels provoked by L. donovani appeared sufficient and optimal because exogenous TNF-alpha administration had no beneficial effect on established infection and continuous high-dose treatment impaired antileishmanial activity. Thus, although not required for granuloma formation, endogenous TNF-alpha appears to be critical to both initial acquisition of resistance to L. donovani and resolution of experimental visceral infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8021511

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  49 in total

1.  Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation.

Authors:  H W Murray
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

2.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis.

Authors:  E Carrillo; S Ahmed; K Goldsmith-Pestana; J Nieto; Y Osorio; B Travi; J Moreno; D McMahon-Pratt
Journal:  Vaccine       Date:  2006-11-10       Impact factor: 3.641

4.  Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis.

Authors:  Blaise Dondji; Eva Pérez-Jimenez; Karen Goldsmith-Pestana; Mariano Esteban; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Cloning of Syrian hamster (Mesocricetus auratus) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis.

Authors:  P C Melby; V V Tryon; B Chandrasekar; G L Freeman
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

6.  Distinct roles for lymphotoxin-alpha and tumor necrosis factor in the control of Leishmania donovani infection.

Authors:  Christian R Engwerda; Manabu Ato; Simona Stäger; Clare E Alexander; Amanda C Stanley; Paul M Kaye
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

7.  Ammonium trichloro [1,2-ethanediolato-O,O']-tellurate cures experimental visceral leishmaniasis by redox modulation of Leishmania donovani trypanothione reductase and inhibiting host integrin linked PI3K/Akt pathway.

Authors:  Preeti Vishwakarma; Naveen Parmar; Pragya Chandrakar; Tanuj Sharma; Manoj Kathuria; Pramod K Agnihotri; Mohammad Imran Siddiqi; Kalyan Mitra; Susanta Kar
Journal:  Cell Mol Life Sci       Date:  2017-09-12       Impact factor: 9.261

8.  Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice.

Authors:  Carole Dumas; Anthony Muyombwe; Gaétan Roy; Claudine Matte; Marc Ouellette; Martin Olivier; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

9.  Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice.

Authors:  Henry W Murray
Journal:  Infect Immun       Date:  2008-06-23       Impact factor: 3.441

10.  Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis.

Authors:  Saeed Ahmed; M Colmenares; L Soong; K Goldsmith-Pestana; L Munstermann; R Molina; Diane McMahon-Pratt
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.